8-K: Ocugen Seeks Court Validation for Share Increase Amid Legal Challenge

Ocugen, Inc. has filed a petition in Delaware Chancery Court to validate a 2024 stockholder vote to increase authorized shares and subsequent share issuances, following a legal challenge.

Summary

• Ocugen, Inc. filed a petition on February 12, 2026, in the Delaware Court of Chancery under Section 205 of the DGCL to validate its Certificate of Amendment, which increased authorized common stock, and all shares issued in reliance on it.
• At the 2024 Annual Meeting on June 28, 2024, stockholders approved a proposal to increase authorized common stock from 295,000,000 to 390,000,000 shares.
• To address low stockholder participation, the company issued Series C Preferred Stock, which amplified the voting power of participating stockholders on the Share Increase Proposal.
• A purported stockholder challenged the approval in October 2024, arguing Series C Preferred Stock was not entitled to vote on charter amendments because it lacked general voting rights in director elections.
• Ocugen filed a Certificate of Correction on May 9, 2025, to clarify the Series C Preferred Stock's voting powers, making it retroactive.
• On October 23, 2025, a class action lawsuit (Prater v. Ocugen, Inc.) was filed, alleging the Share Increase Proposal was not properly approved, the Certificate of Amendment was invalid, and the company issued 'ultra vires' shares.
• The plaintiff in the class action lawsuit does not oppose Ocugen's Section 205 petition and has agreed that a favorable ruling would moot her claims.
• As of January 22, 2026, Ocugen had issued 33,009,874 shares of common stock in reliance on the validity of the Charter Amendment.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative development due to the significant legal uncertainty surrounding the company's capital structure and past share issuances, despite the proactive steps taken to resolve it. The potential for adverse outcomes, though mitigated by the plaintiff's non-opposition, still presents a material risk.

Positives

• Ocugen is proactively seeking judicial validation to resolve uncertainty regarding its capital structure and past share issuances.
• The plaintiff in the related class action lawsuit does not oppose the Section 205 petition, indicating a potential path to resolution without prolonged adversarial litigation.
• The company's board unanimously approved the Share Increase Proposal, demonstrating internal alignment on the need for increased authorized shares.
• The company's intent behind the Series C Preferred Stock was to address historical low stockholder participation and ensure flexibility for equity financing and incentive compensation.

Negatives

• The validity of a significant stockholder vote and subsequent issuance of over 33 million shares is under legal challenge, creating substantial uncertainty.
• The company faces allegations of issuing 'ultra vires' shares, which could have severe consequences if not validated.
• The situation highlights a potential past corporate governance oversight regarding the precise voting rights of the Series C Preferred Stock.
• Ocugen has historically struggled to achieve quorum at its annual meetings, indicating ongoing challenges with stockholder engagement.

Risks

• Uncertainty regarding the outcome of the Section 205 proceeding, as no assurances can be made.
• The litigation process inherently involves risks and could have an adverse effect on the Company.
• If the Charter Amendment and subsequent share issuances are not validated, it could lead to severe consequences, including paralyzing the company's ability to use newly issued shares for fundraising and other corporate purposes.
• Inability to determine the stockholders entitled to vote in a Section 204 ratification if the issued shares are deemed invalid, making self-help ratification impractical.
• Substantial costs and risks associated with a Section 204 ratification vote due to potential lack of stockholder participation.

Future Outlook

The company is seeking court validation to resolve the uncertainty surrounding its Share Increase Proposal and subsequent share issuances. It hopes the petition will be granted, validating these corporate acts and mooting the related class action lawsuit. However, no assurances can be made regarding the outcome of the proceeding, and the litigation could have an adverse effect on the company.

Management Comments

• The Company disputed the stockholder's construction of the charter regarding the Series C Preferred Stock's voting rights.
• The Company disputes the allegations in the Stockholder Action.
• The Company believes that no stockholders could have been substantially or adversely affected by the Certificate of Correction, especially given the disclosures made prior to the 2024 Annual Meeting.

Industry Context

StockSavvy.ai notes that the use of super-voting preferred stock, such as Ocugen's Series C Preferred Stock, to address low retail investor participation and quorum challenges is a complex corporate governance strategy. While intended to ensure the will of engaged stockholders is respected, it can lead to legal challenges regarding compliance with charter provisions and state corporate law, as seen in this case. The reliance on Section 205 of the Delaware General Corporation Law highlights Delaware's established mechanism for resolving such corporate act defects, a common recourse for companies incorporated in the state facing authorization issues.

Comparison to Industry Standards

• Delaware General Corporation Law (DGCL) Section 205 provides a mechanism for validating defective corporate acts, which is a standard legal recourse for Delaware-incorporated companies facing such challenges, aligning with established legal frameworks.
• The use of 'super-voting' preferred stock to address low retail investor participation and quorum issues is a known, albeit sometimes controversial, strategy in corporate governance, often employed by companies struggling with shareholder engagement, similar to practices observed in other companies with dispersed retail ownership.
• The specific voting threshold requirement ('majority of the voting power of all of the then-outstanding shares... entitled to vote generally in the election of directors') is a common provision in corporate charters, and its precise interpretation is critical for the validity of corporate actions, reflecting standard corporate law principles.
• The company's proactive approach to seek judicial validation, with the plaintiff's non-opposition, suggests a path towards resolution that aligns with best practices for mitigating legal and operational uncertainty in corporate governance disputes, aiming for a more efficient resolution than protracted litigation.

Corporate Governance

Legal Proceedings

• **Prater v. Ocugen, Inc., C.A. No. 2025-1214-NCC (Del. Ch.):** A putative class action lawsuit filed on October 23, 2025, by Megan Prater, a purported stockholder. The complaint alleges that the Share Increase Proposal was not properly approved because the Series C Preferred Stock was not authorized to vote generally in the election of directors, rendering the Certificate of Amendment invalid and subsequent share issuances ultra vires. Plaintiff also asserts the Certificate of Correction is invalid and cannot operate retroactively.
• **In re Ocugen, Inc., C.A. No. 2026-0210-NAC (Del. Ch.):** Ocugen's verified petition filed on February 12, 2026, under Section 205 of the DGCL. The company seeks judicial validation of the Certificate of Amendment that increased its authorized shares and all shares of common stock issued in reliance on its effectiveness and validity. The plaintiff in the Prater v. Ocugen, Inc. action does not oppose this petition and has agreed that a favorable ruling would moot her claims.

Stakeholder Impact

• **Shareholders:** Face uncertainty regarding the validity of shares issued after July 10, 2024, in reliance on the Charter Amendment. All shareholders are impacted by the legal cloud over the company's capital structure and the potential for adverse outcomes if validation is denied.
• **Employees and Executives:** Potential impact on equity incentive awards, as the ability to grant new shares was a key reason for the share increase, and the validity of such grants could be questioned.
• **Potential Investors:** May be hesitant to invest due to the ongoing legal challenge and the uncertainty surrounding the company's capital structure and the validity of its outstanding shares.
• **Company Operations:** The company's ability to use newly issued shares for fundraising, strategic growth, and other corporate purposes could be paralyzed if the court declines to validate the corporate acts.

Next Steps

• Stockholders of the Company may appear at the hearing or file a written submission by April 16, 2026, to express a position on the Petition.
• A hearing on the Petition is set for May 6, 2026, at 1:30 pm Eastern Time at the Leonard L. Williams Justice Center, Wilmington, Delaware.
• The Company will continue to detail risks in its filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent SEC filings.

Key Dates

Recommendation

While the legal challenge introduces significant uncertainty and risk regarding Ocugen's capital structure and past share issuances, the company is proactively addressing it through a Section 205 petition. The plaintiff's non-opposition to this petition suggests a potential path to resolution, which mitigates some of the immediate downside. However, the outcome is not guaranteed, and the fundamental issue of potentially 'putative stock' warrants caution. A 'hold' recommendation reflects waiting for the court's decision before making a more definitive investment move, acknowledging both the risks and the company's efforts to resolve them.

Keywords

SEC filing, 8-K, Ocugen, OCGN, Delaware Court of Chancery, Section 205, Share Increase Proposal, Authorized Shares, Common Stock, Series C Preferred Stock, Corporate Governance, Stockholder Vote, Certificate of Amendment, Certificate of Correction, Putative Stock, Class Action Lawsuit, Equity Financing, Risk Management